Santhera Pharmaceuticals AG, of Pratteln, Switzerland, reported a 38% increase in net revenues in 2018 to CHF31.7 million (US$31.09 million) from continued growth in sales of its lead product Raxone (idebenone) for the treatment of Leber's hereditary optic neuropathy (LHON).